Washington Trust Got Its Margin Back — and Stopped Waving Off Its Own Stock
A 44-basis-point NIM jump, a loan-to-deposit ratio at a level it 'has rarely been at,' and a CEO who now says the shares are simply too pricey to buy
WASH · Earnings Call · 2026-10-20
The margin finally stops apologizing
For six quarters the story at Washington Trust was what credit was doing to the income statement. That flipped on Tuesday. Net interest income hit $44.7 million — the highest quarterly figure in the ten years this dataset covers — and net interest income is now up 15% year-over-year, with pre-provision pre-tax net revenue up 20% sequentially and 26% annually. “The margin was 284, up by 11 basis points from Q2 and up by 44 basis points year-over-year.” — Ron Ohsberg, Chief Financial Officer · 2026-10-20 Net income of $19.4 million, or $1.01 a share, beat the prior quarter by $0.18.What matters more is the guidance chain. In January the company pointed to a Q4 2026 margin of 2.78%–2.82%. In April that slipped to 2.75%–2.80%. In July, Ron Ohsberg told analysts “We're looking at, say, 2.75% for Q3 and 2.80% for Q4.” — Ronald Ohsberg, Chief Financial Officer · 2026-07-21 He delivered 2.84% and now guides Q4 to 2.85%–2.90%, with the September spot margin already at 2.85%. That is a beat-and-raise cadence, not a defensive hold.The catch is that not all of the 11 basis points is organic. Roughly 2 basis points came from $283,000 of second-quarter interest income recognized on a loan returned to accrual, and non-interest income of $18.5 million carried a $954,000 bank-owned life insurance gain. Strip those out and the margin is still improving — the terminated swap benefit of 2–3 basis points is now fully baked, as promised — but the incremental run-rate is thinner than the headline.The problem with 'quality assets'
The single highest-momentum phrase in Washington Trust's own Q3 corpus is quality assets, and it is not a compliment. It is Ned Handy describing what a hiking cycle does to the asset side of a lender that competes for commercial real estate paper:“what we're seeing in the market in general is spreads are tightening as rates rise... we're seeing spreads in the, I don't know, 170s, 180s for high-quality assets. So that bites into that benefit a little bit. And obviously, there's a lot of competition for quality assets.” — Ned Handy, Chairman and Chief Executive Officer · 2026-10-20That is the tension in this report. “We think that each 25 basis point hike probably gives us 1-2 basis points on the run rate.” — Ron Ohsberg, Chief Financial Officer · 2026-10-20 One to two basis points per 25 — that is a modest rate hike sensitivity for a bank that was liability-sensitive for most of the last two years. A year ago the framing was the opposite: “we're a lot less liability sensitive than we were last fall when the Fed was cutting.” — Ronald Stephen Ohsberg, Chief Financial Officer · 2025-07-22 The regime turned, and Washington Trust is now on the right side of it — but only just, and with the benefit leaking into loan spreads.This is also emphatically not a company-unique story. The global Q3 keyword set is saturated with bank income-statement vocabulary — retail deposits, loan beta, deposit spread, recent rate increases — and on the same day half the regional-bank tape said a version of the same thing: AUB on Fed increases, HOMB on 'a couple rate hikes,' HBCP on a high-rate environment, WTFC on increased sensitivity to higher rates, ZION and USB on rate-environment influence. Washington Trust is riding a broad wave, not ahead of it.The differentiated part is the funding side. Deposits reached $5.4 billion, up 4% year-over-year and 1% sequentially, with wholesale funding cut 18%. “we're very pleased with our loan-to-deposit ratio, which is at a low level that we've rarely been at in the past.” — Ron Ohsberg, Chief Financial Officer · 2026-10-20 The engine is the institutional banking team, whose operating accounts are driving non-interest-bearing growth and which the company expects to self-fund a meaningful share of its own production. That is a genuine deposit growth story rather than a price-your-way-into-it one.Credit: the office chapter closes, mostly
Non-accrual loans fell to 48 basis points from 78, past dues to 54 from 81. The driver was the long-running $22.3 million office credit: $18.5 million returned to accrual, $3.8 million charged off, provision of $1.8 million. A year ago Bill Wray was being pressed on a 70% markdown on a Connecticut office sale — “But in fairness, Bill, you felt comfortable last quarter with the $2.3 million reserve on that loan as well.” — Mark Fitzgibbon, Analyst · 2025-10-21 The tone on Tuesday was a different man. When asked why a $6 million Class A office loan was newly ticked into non-performers despite never missing a payment, Wray attributed it to “potential valuation risk” — Bill Wray, Credit Officer · 2026-10-20 — a valuation risk marker rather than a cash-flow problem. The $28 million lab property is 95% leased with free rent burning off, near a move out of special mention. The office office loan tail is shrinking.The capital answer changed its reasoning
Laurie Hunsicker has asked about buybacks on at least three consecutive calls. For quarters the answer was capital ratios — “we are on the lower end of the range on capital ratios. We're aware of that.” — Ronald Ohsberg, Chief Financial Officer · 2025-10-21 In April it was “we maintain a buyback program, but we really are not at this point intending to be buying back shares.” — Ronald Ohsberg, Chief Financial Officer · 2026-04-21 On Tuesday, the reason became price:Seconds later Ohsberg undercut the 'we've got the capital' half of that sentence: “our GAAP capital ratios remain on the lighter side of the peer group. We recognize that.” — Ron Ohsberg, Chief Financial Officer · 2026-10-20 Both things can be true — the regulatory ratios are fine, the GAAP ones are not — but the two men are answering different questions. Share repurchases totaled roughly $0.6 million in the latest reported quarter, against a $9 million peak in 2023. Meanwhile the stock sits at 1.3x book — cheap against its own history, expensive against the last twelve months.And the tape has already voted. The shares are up 9.7% over 90 trading days, roughly 42% over the last year, and sit 5.3% below a September 4 high of $40.26. Nothing in the broader market's recent momentum is bank-related — the 90-day movers are biotech and energy — so this is a company-level re-rating, and management is telling you they would rather lend into a $230 million pipeline “weighted towards C&I” — Ned Handy, Chairman and Chief Executive Officer · 2026-10-20 than buy the stock.We don't have any plans to buy stock back at this point. The price is high. We've got the capital. We've got other things to invest in.